Step towards artificial pancreas

Sensor-augmented insulin pump therapy with low-glucose-suspend (LGS) functionality is an important step towards a fully automated closed loop “artificial pancreas” system, say Australian researchers.

Their six-month clinical evaluation found the devices are more cost effective than standard pump therapy in patients with type 1 diabetes who have impaired awareness of hypoglycaemia.

They report a higher incidence of severe hypoglycaemic events occurring in patients using a standard pump compared with an LGS group during the Medtronics-funded study.